Wells Fargo’s Stemline Therapeutics, Inc. STML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-26,730
| Closed | -$129K | – | 7197 |
|
|
2020
Q1 | $129K | Sell |
26,730
-2,685
| -9% | -$17.4K | ﹤0.01% | 4937 |
|
|
2019
Q4 | $313K | Sell |
29,415
-42,010
| -59% | -$417K | ﹤0.01% | 4707 |
|
|
2019
Q3 | $744K | Buy |
71,425
+8,786
| +14% | +$115K | ﹤0.01% | 4075 |
|
|
2019
Q2 | $960K | Sell |
62,639
-2,152
| -3% | -$31.1K | ﹤0.01% | 3894 |
|
|
2019
Q1 | $832K | Buy |
64,791
+49,783
| +332% | +$563K | ﹤0.01% | 4019 |
|
|
2018
Q4 | $143K | Buy |
15,008
+752
| +5% | +$9.75K | ﹤0.01% | 5104 |
|
|
2018
Q3 | $237K | Buy |
14,256
+924
| +7% | +$14.8K | ﹤0.01% | 4915 |
|
|
2018
Q2 | $214K | Sell |
13,332
-1,346
| -9% | -$24K | ﹤0.01% | 4996 |
|
|
2018
Q1 | $224K | Sell |
14,678
-112
| -0.8% | -$1.75K | ﹤0.01% | 4922 |
|
|
2017
Q4 | $230K | Sell |
14,790
-230
| -2% | -$3.08K | ﹤0.01% | 4892 |
|
|
2017
Q3 | $167K | Buy |
15,020
+1,373
| +10% | +$12.9K | ﹤0.01% | 5010 |
|
|
2017
Q2 | $126K | Hold |
13,647
| – | – | ﹤0.01% | 5064 |
|
|
2017
Q1 | $117K | Buy |
13,647
+500
| +4% | +$4.56K | ﹤0.01% | 5133 |
|
|
2016
Q4 | $140K | Buy |
13,147
+5,313
| +68% | +$64.3K | ﹤0.01% | 4960 |
|
|
2016
Q3 | $84K | Hold |
7,834
| – | – | ﹤0.01% | 5020 |
|
|
2016
Q2 | $53K | Sell |
7,834
-345
| -4% | -$2.18K | ﹤0.01% | 5179 |
|
|
2016
Q1 | $36K | Buy |
8,179
+290
| +4% | +$1.42K | ﹤0.01% | 5343 |
|
|
2015
Q4 | $50K | Buy |
7,889
+4
| +0.1% | +$32 | ﹤0.01% | 5282 |
|
|
2015
Q3 | $70K | Sell |
7,885
-698
| -8% | -$7.32K | ﹤0.01% | 5119 |
|
|
2015
Q2 | $101K | Buy |
8,583
+6,442
| +301% | +$89.4K | ﹤0.01% | 5053 |
|
|
2015
Q1 | $31K | Buy |
2,141
+604
| +39% | +$9.24K | ﹤0.01% | 5212 |
|
|
2014
Q4 | $26K | Buy |
1,537
+4
| +0.3% | +$58 | ﹤0.01% | 5259 |
|
|
2014
Q3 | $19K | Sell |
1,533
-290
| -16% | -$3.57K | ﹤0.01% | 5340 |
|
|
2014
Q2 | $27K | Buy |
1,823
+1,820
| +60,667% | +$27.9K | ﹤0.01% | 5241 |
|
|
2014
Q1 | $0 | Hold |
3
| – | – | ﹤0.01% | 6178 |
|
|
2013
Q4 | $0 | Sell |
3
-98
| -97% | -$2.62K | ﹤0.01% | 6023 |
|
|
2013
Q3 | $5K | Buy |
+101
| New | +$3.29K | ﹤0.01% | 5298 |
|
Wells Fargo's STML Position: Q2 2020 in Review
Wells Fargo sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 26,730 shares — an estimated $129K sold.
Wells Fargo first reported a position in STML in Q3 2013 and held it in 27 quarters. The position peaked at $960K in Q2 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.
- Wells Fargo reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
- Wells Fargo sold 26,730 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $129K.
- Wells Fargo first reported a position in Stemline Therapeutics, Inc. in Q3 2013 and held it in 27 quarters.
- Wells Fargo's Stemline Therapeutics, Inc. position peaked at $960K in Q2 2019.
- 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.
Based on Wells Fargo's 13F filing for Q2 2020, filed 13 Aug 2020.